CELGENE$70.72
-0.48
| Last Trade: |
70.72 |
| Trade Time: |
May 16 4:19 PM Eastern Daylight Time |
| Change: |
-0.48 (-0.67 %) |
| Prev Close: |
71.20 |
| Open: |
71.24 |
| Bid: |
70.54 |
| Ask: |
70.93 |
Quotes displayed are delayed by 15 minutes. Market data is provided by Telvent DTN
|
Date |
Name |
Title |
Volume |
Trade Price |
Holding Change |
|
5/4/2012
|
DRAKE RODMAN L
|
Director
|
500
|
$69.87
|
4.15%
|
|
4/27/2012
|
DRAKE RODMAN L
|
Director
|
300
|
$72.53
|
2.66%
|
|
4/27/2012
|
MARIO ERNEST
|
Director
|
4,625
|
$49.93
|
9.97%
|
|
4/27/2012
|
MARIO ERNEST
|
Director
|
12,333
|
$44.94
|
24.18%
|
|
4/27/2012
|
DRAKE RODMAN L
|
Director
|
500
|
$72.92
|
4.33%
|
Data provided by Insiderslab.com. To read detailed Insider Trading Research Report for (CELG), click here.
-
Onyx Pharmaceuticals Inc. (ONXX) recently announced that the U.S. Food and Drug Administration's (FDA) advisory committee is scheduled to review the company's new drug application (NDA) for Kypr ...
Read More »
-
Fast growers are starting to outperform value stocks more sensitive to the economic climate, writes MoneyShow.com senior editor Igor Greenwald.
What does a wary market do when it learns the Federal ...
Read More »
-
Strong pipelines for the biotech sector as well as a wave of merger activity, have investors flocking to the stocks.
Read More »
-
While the first half of 2012 is shaping up nicely, the second half is a bit worrisome, writes Elliott Gue of Personal Finance.
The US economy enters 2012 with significant positive momentum. Growt ...
Read More »
-
Pfizer has to convince the Street that it can still grow, but the stock is cheap for now.
Read More »
-
XOMA changes management again, but should anybody care?
Read More »
Free Reports
|
|
